Citation Impact
Citing Papers
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
2014 Standout
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer
2018
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
2016 Standout
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
2015
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
2011
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
T Regulatory Cells Support Plasma Cell Populations in the Bone Marrow
2017 StandoutNobel
Regulatory T-cell directed therapies in liver diseases
2013 StandoutNobel
ENTPD1/CD39 is a promising therapeutic target in oncology
2012
Biomaterials based on chitin and chitosan in wound dressing applications
2011 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Biological activities and pharmaceutical applications of polysaccharide from natural resources: A review
2017 Standout
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
2013
Modulation of the SDF-1–CXCR4 axis by the third complement component (C3)—Implications for trafficking of CXCR4+ stem cells
2006
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
Elevated Pre–Antiretroviral Therapy CD39+CD8+ T Cell Frequency Is Associated With Early Mortality in Advanced Human Immunodeficiency Virus/Tuberculosis Co-infection
2017 StandoutNobel
Innate and adaptive immune cells in the tumor microenvironment
2013 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche
2011 Nature
Mammalian phosphoinositide kinases and phosphatases
2009 StandoutNobel
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
2014
Regulatory T Cells
2010
Isolation, structures and bioactivities of the polysaccharides from jujube fruit (Ziziphus jujuba Mill.): A review
2017 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
The immune contexture in cancer prognosis and treatment
2017 Standout
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
2010
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Antitumor activity of mushroom polysaccharides: a review
2012
Complement: a key system for immune surveillance and homeostasis
2010 Standout
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Fifth complement cascade protein (C5) cleavage fragments disrupt the SDF-1/CXCR4 axis: Further evidence that innate immunity orchestrates the mobilization of hematopoietic stem/progenitor cells
2010
Effect of Beta Glucan on White Blood Cell Counts and Serum Levels of IL-4 and IL-12 in Women with Breast Cancer Undergoing Chemotherapy: A Randomized Double-Blind Placebo-Controlled Clinical Trial
2014
DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma
2009
Structure–function relationships of immunostimulatory polysaccharides: A review
2015 Standout
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy
2015
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Cancer immunotherapy
2012
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
2009
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
2017 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Anticancer polysaccharides from natural resources: A review of recent research
2012
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
2009 Standout
Regulatory T cells in cancer immunotherapy
2014 StandoutNobel
Neutrophils in cancer: neutral no more
2016 Standout
Defining trained immunity and its role in health and disease
2020 Standout
Neutrophils as effector cells for antibody-based immunotherapy of cancer
2012
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
Differential regulation of oxidative burst by distinct β-glucan-binding receptors and signaling pathways in human peripheral blood mononuclear cells
2014
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
Macrophage Polarization
2016 Standout
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
2011 Standout
The Emerging Role of Immunosurveillance in Dictating Metastatic Spread in Breast Cancer
2013
Clinical and Physiological Perspectives of β-Glucans: The Past, Present, and Future
2017
Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”
2014
Polysaccharides in Lentinus edodes : Isolation, Structure, Immunomodulating Activity and Future Prospective
2012
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
2017 Standout
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Neutrophils in the Tumor Microenvironment
2015
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
2016
Regulation of FcγR-stimulated phagocytosis by the 72-kDa inositol polyphosphate 5-phosphatase: SHIP1, but not the 72-kDa 5-phosphatase, regulates complement receptor 3–mediated phagocytosis by differential recruitment of these 5-phosphatases to the phagocytic cup
2007
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
2014 StandoutNobel
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
2017 Standout
Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma
2012
Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
2010
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
2014 Standout
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
2013 Standout
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Preparation and evaluation of a novel wound dressing sheet comprised of β-glucan–chitosan complex
2010
In vivoInhibition of Human CD19-Targeted Effector T Cells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B Cell Malignancy
2011
Works of Daniel Cramer being referenced
Transient T cell depletion causes regression of melanoma metastases
2008
Therapeutic potential of various β-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy
2009
Yeast glucan particles activate murine resident macrophages to secrete proinflammatory cytokines via MyD88- and Syk kinase-dependent pathways
2007
Combined Yeast β-Glucan and Antitumor Monoclonal Antibody Therapy Requires C5a-Mediated Neutrophil Chemotaxis via Regulation of Decay-Accelerating Factor CD55
2007
Matching at the MHC class I K locus is essential for long-term engraftment of purified hematopoietic stem cells: a role for host NK cells in regulating HSC engraftment
2004
Yeast-Derived β-Glucan Augments the Therapeutic Efficacy Mediated by Anti–Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models
2008
Mobilization of Hematopoietic Progenitor Cells by Yeast-Derivedβ-Glucan Requires Activation of Matrix Metalloproteinase-9
2008
A Novel Role of Complement in Mobilization: Immunodeficient Mice Are Poor Granulocyte-Colony Stimulating Factor Mobilizers Because They Lack Complement-Activating Immunoglobulins
2007
Yeast β-Glucan Amplifies Phagocyte Killing of iC3b-Opsonized Tumor Cells via Complement Receptor 3-Syk-Phosphatidylinositol 3-Kinase Pathway
2006
β-Glucan enhances complement-mediated hematopoietic recovery after bone marrow injury
2005